Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
Johnson & Johnson's Upcoming Lung Cancer Data Could Offer Another Blockbuster Opportunity, Says Analyst
06:21pm, Thursday, 02'nd Feb 2023 Benzinga
Cantor Fitzgerald is previewing its thoughts on a potential interim analysis for Johnson & Johnson's (NYSE: JNJ) Phase 3 MARIPOSA study of Rybrevant (amivantamab) + lazertinib in first-line epide
GSK's Daprodustat Drug for Anemia Due to CKD Gets FDA Nod
06:04pm, Thursday, 02'nd Feb 2023
GSK announces the FDA approval of daprodustat for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least four months.
AstraZeneca: Will pharma giant beat revenue expectations?
09:56am, Thursday, 02'nd Feb 2023
AstraZeneca PLC (LSE:AZN) is poised to release its full-year results for 2022 on February 9, with shareholders hoping for the pharmaceutical giant to beat upgraded guidance outlined in November 2022
U.S. Appeals Court Sides With Drugmakers on Discount Program
02:38pm, Monday, 30'th Jan 2023
The court ruled that drugmakers can limit their shipments of federally-discounted drugs to pharmacies, in a blow to hospitals and clinics.
FDA Pulls EUA Granted to AstraZeneca's (AZN) Evusheld
12:02pm, Friday, 27'th Jan 2023
AstraZeneca's (AZN) Evusheld is no longer authorized for use in the United States after laboratory data showed that it does not neutralize Omicron subvariants.
Mergers and Acquisitions in 2023 Off To A Strong Start
08:17am, Friday, 27'th Jan 2023
Mergers and acquisitions are a normal part of business, but 2023 has already presented many opportunities across the biotech industry. The M&A surge seems to be driven by two major transactions: the $
7 Dividend Stocks to Buy for a Stable Income Stream
06:45am, Friday, 27'th Jan 2023
A key to successful retirement planning or wealth building is to start early. One critical component of investing is to secure stable cash flows.
FDA withdraws Covid antibody treatment Evusheld because it's not effective against 93% of subvariants
11:20pm, Thursday, 26'th Jan 2023
Many take Evusheld as an additional layer of protection because the vaccines do not trigger a strong immune response for them.
AstraZeneca's preventive COVID therapy no longer effective against current variants
01:49pm, Thursday, 26'th Jan 2023
AstraZeneca AZN, -1.32% AZN, -1.54% said Thursday that the Food and Drug Administration is no longer allowing healthcare providers to prescribe Evusheld, a therapy authorized for pre-exposure prophyla
The Top Healthcare Stocks to Buy With $100
05:35am, Monday, 23'rd Jan 2023
Don't overlook these big-name foreign healthcare stocks.
AstraZeneca chair: Health care systems around the world can benefit from investment in technology
01:37pm, Wednesday, 18'th Jan 2023
Leif Johansson, chairman at AstraZeneca, speaks to CNBC's Karen Tso at Davos 2023.
AIM ImmunoTech shares rise on news of pancreatic cancer research partnership with AstraZeneca and Erasmus Medical Center
10:26am, Tuesday, 17'th Jan 2023
AIM ImmunoTech Inc (NYSE:AIM) (AIM) announced that it has entered into an external sponsored collaborative clinical research agreement with AstraZeneca and Erasmus Medical Center in the Netherlands t
3 Growth Stocks Poised for Huge Gains in 2023
07:50am, Saturday, 14'th Jan 2023
These big pharmaceuticals are poised for back-to-back big years.
FDA approves AstraZeneca's new treatment for people with asthma
08:38am, Wednesday, 11'th Jan 2023
AstraZeneca AZN, +0.99% AZN, -0.27% said Wednesday that the Food and Drug Administration approved a new therapy that can be used to treat or prevent bronchoconstriction in adults with asthma. Thee com
AstraZeneca Stock Nabs Breakout After $1.8 Billion CinCor Buyout
11:56am, Tuesday, 10'th Jan 2023
AstraZeneca stock edged into breakout territory on Tuesday, a day after announcing its $1.8 billion plan to acquire CinCor Pharma. The post AstraZeneca Stock Nabs Breakout After $1.8 Billion CinCor Bu
